Doctors studied a new, non-invasive way to monitor a serious brain inflammation condition called anti-NMDAR encephalitis. They followed one female patient in her early 30s who was being treated for the condition, including with a drug called methotrexate. They compared her to one healthy woman of the same age. The goal was to see if tiny particles from brain cells, which can be found in urine, could give clues about what was happening inside the brain.
Over 34 days of treatment, the researchers measured levels of a key brain protein called GluN1 in these urine particles. They found two patterns. First, the overall level of the protein went down over time, which matched what they saw in the patient's spinal fluid. Second, the protein level temporarily increased about 48 hours after each methotrexate infusion, creating a wave-like pattern.
This is a detailed report on just one patient. The researchers did not report any safety problems or side effects from this monitoring method itself. The main reason to be careful is that findings from a single person cannot be applied to others. The temporary increases after the drug might be related to how the drug works, but this is still a guess. Readers should see this as an interesting first step in research, showing it might be possible to track brain changes through urine. It is not a proven tool for doctors to use, and much more work is needed.
